Calcifediol monohydrate (25-hydroxyvitamin D3 monohydrate) is a potent VDR ligand and vitamin D supplement. Calcifediol is a precursor of the Vitamin D Endocrine System (VDES), which is hydroxylated in the liver to produce the active form of calcitriol. Calcifediol rapidly raises serum levels of Calcifediol rapidly increases serum levels of vitamin D.
White or almost white crystals.
Calcifediol is a major circulating metabolite of vitamin D3 and acts as a competitive inhibitor with an apparent Ki of 3.9 μM. It is produced in the liver and is the best indicator of the body’s vitamin D stores. It is effective in the treatment of ricket
25-Hydroxyvitamin D3 may be used as a certified reference material (CRM) for the determination of the analyte in biological samples by chromatography techniques.
ChEBI: Calcifediol monohydrate is a vitamin D.
A Certified Spiking Solution of 25-Hydroxyvitamin D3, a prohormone whose blood serum levels are used to determine Vitamin D nutritional status. This solution standard is suitable for critical quantitative applications in research and clinical environments including: for use in preparation of controls and calibrators for LC/UV and LC-MS/MS assays; as system tuning/suitability standards; linearity verification; internal proficiency testing; and for OEM use in preparation of reagents, development of assays and instrument IQ/OQ. The stable, quantitative solution format provides significant benefits to the user including material savings, increased efficiency of labor, and convenience of use. The shelf stable Snap-N-Spike format allows laboratories to eliminate painstaking weighing operations and provides the ability to spike a known concentration of analyte into their matrix of choice just before use.
Cholecalciferol is an inactive form of vitamin D3 which undergoes various levels of hydroxylation to form active vitamin D3 analogs. 1α-Hydroxyvitamin D3 (alfacalcidol) is a synthetic analog that is metabolized to 1,25-dihydroxycholecalciferol, the biologically active form of vitamin D3. Other analogues of cholecalciferol result from different hydroxylations. 25-dihydroxycholecalciferol is a the major circulating form of vitamin D3 and a physiological precursor of 1α,25-Dihydroxycholecalciferol. The conversion is catalyzed by 25-Hydroxyvitamin D3 1-α-hydroxylase (VD3 1A hydroxylase) also known ascytochrome p450 27B1 (CYP27B1).
Common side effects of Calcifediol Monohydrate include: constipation, runny or stuffy nose, sneezing, sore throat. Some patients may experience joint pain. Serious side effects may include: feeling tired, difficulty thinking, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination or weight loss, shortness of breath, pale skin, broken bones, and severe allergic reactions. If any of these serious adverse reactions occur, please seek medical attention immediately.
The European Chemicals Agency (ECHA)- external site hazard classification and labeling for calcifediol monohydrate is 'Danger! According to the classification provided by companies to ECHA in CLP notifications, this substance is fatal if swallowed, is fatal in contact with skin, is fatal if inhaled, causes damage to organs through prolonged or repeated exposure, is suspected of damaging fertility or the unborn child and may cause long lasting harmful effects to aquatic life'.
Calcidiol monohydrate contains the monohydrate form of the major circulating metabolite of vitamin D3 in the body and is a source of 1,25-dihydroxyvitamin D, the biologically active form of vitamin D. Calciferol monohydrate (25-hydroxycholecalciferol monohydrate) is safe under recommended conditions and level of use (up to 10 μg/day) and is safe for children >11 years of age and adults, including pregnant and lactating women.
